Results 211 to 220 of about 138,032 (344)

High pretreatment peripheral blood T‐cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology

British Journal of Haematology, EarlyView.
Left panel: Scheme of the XPAG‐immune thrombocytopenia trial. The dexamethasone (DEX) arm consisted of DEX 40 mg/day for days 1–4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag (ETB) + DEX received eltrombopag in combination with a short course of high‐dose DEX beginning on
Paul Schmidt‐Barbo, Christoph Schultheiss, Annaïse J. Jauch, Donjetë Simnica, Gerda Silling, Mathias Hänel, Jörg Chromik, Thomas Stauch, Karolin Trautmann‐Grill, Roland Repp, Clemens Schulte, Bastian Fleischmann, Manfred Welslau, Martina Stauch, Claudia Quiering, Frank Richter, Tamara Tesanovic, Sabine Jahn, Andreas Holbro, Jakob R. Passweg, Axel Matzdorff, Mathias Rummel, Oliver Meyer, Falk Nimmerjahn, Mascha Binder   +24 more
wiley   +1 more source

Cyclic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia (ITP): Diagnostic and Therapeutic Lessons. [PDF]

Cureus
Seeburun S, Lee E, Salameh S, Eltoukhy H.   +3 more
europepmc   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

Cancer Science, EarlyView.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

Third‐Generation EGFR‐TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

Cancer Science, EarlyView.
This study was the largest sample size of first‐line third‐generation TKIs combined chemotherapy among advanced EGFRm NSCLC patients in the real world. It was never reported that aumolertinib and furmonertinib showed comparable PFS benefits to osimertinib in combination with chemotherapy. The overall safety profile remained acceptable. ABSTRACT FLAURA2
YuQin Jiang, Qi Liang, Yuting Zhu, Xiao Liang, Ruohan Huang, Wenxin Zhou, Chen Zhang, Jun Li, Jiali Xu, Renhua Guo   +9 more
wiley   +1 more source

Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. [PDF]

Immunotherapy
Kuter DJ, Ghanima W.
europepmc   +1 more source

Splenic pathology in immune thrombocytopenia. [PDF]

, 1985
Malcolm Hayes, Peter Jacobs, L. Wood, D M Dent   +3 more
openalex   +1 more source

Inborn errors of immunity: Rare cause of chronic immune thrombocytopenia

, 2023
Safquat Jalil, Harshita Chaudhary, Abhinav Vishwakarma, Ahmed Jamal, Bal Mukund, M.K. Safal Muhammed   +5 more
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Platelet Count of Zero: A Case of Vancomycin-Induced Immune Thrombocytopenia. [PDF]

Cureus
Gakhar SB, Hurwitz A, Sellars C, Willinger A, Cheing M.   +4 more
europepmc   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources